| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,800,000 |
| Market
Cap: |
151.42(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.4 - $9.48 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kodiak Sciences is a biopharmaceutical company focused on researching, developing and commercializing therapeutics to treat high prevalence retinal diseases. Co.'s Antibody Biopolymer Conjugate Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. Co.'s main product candidate, KSI-301, is an anti-vascular endothelial growth factor antibody biopolymer conjugate for the treatment in retinal vascular diseases including wet age-related macular degeneration (AMD), diabetic macular edema and retinal vein occlusion. Co.'s pipeline, including product candidates KSI-501 and KSI-601, are used for other needs in retina such as dry AMD and glaucoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,379,445 |
| Total Buy Value |
$0 |
$0 |
$0 |
$9,508,745 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
9 |
| Total Shares Sold |
0 |
0 |
7,587 |
15,417 |
| Total Sell Value |
$0 |
$0 |
$70,517 |
$126,006 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
4 |
8 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baker Felix |
Director |
– • • |
2022-05-25 |
4 |
B |
$6.53 |
$664,135 |
I/I |
101,144 |
15,232,546 |
2.25 |
20% |
|
| Baker Felix |
Director |
– • • |
2022-05-18 |
4 |
B |
$5.95 |
$1,335,419 |
I/I |
223,766 |
15,142,074 |
2.25 |
34% |
|
| Baker Felix |
Director |
– • • |
2022-05-17 |
4 |
B |
$5.99 |
$663,571 |
I/I |
110,824 |
14,942,601 |
2.25 |
25% |
|
| Baker Felix |
Director |
– • • |
2022-05-16 |
4 |
B |
$5.71 |
$697,839 |
I/I |
122,100 |
14,843,809 |
2.25 |
34% |
|
| Perlroth Victor |
Chairman and CEO |
• • • |
2022-02-25 |
4 |
S |
$8.99 |
$3,055,988 |
D/D |
(340,000) |
2,168,038 |
|
-14% |
|
| Perlroth Victor |
Chairman and CEO |
• • • |
2022-02-24 |
4 |
S |
$9.20 |
$9,201,700 |
D/D |
(1,000,000) |
2,508,038 |
|
11% |
|
| Baker Felix |
Director |
– • • |
2022-02-17 |
4 |
B |
$53.82 |
$16,367,881 |
I/I |
300,000 |
14,734,965 |
2.25 |
-85% |
|
| Baker Felix |
Director |
– • • |
2022-02-16 |
4 |
B |
$53.73 |
$5,150,173 |
I/I |
95,165 |
14,457,794 |
2.25 |
-86% |
|
| Baker Felix |
Director |
– • • |
2022-02-15 |
4 |
B |
$54.16 |
$314,099 |
I/I |
5,800 |
14,369,871 |
2.25 |
-85% |
|
| Baker Felix |
Director |
– • • |
2022-01-31 |
4 |
B |
$57.22 |
$1,725,084 |
I/I |
30,148 |
14,364,512 |
2.25 |
-86% |
|
| Baker Felix |
Director |
– • • |
2022-01-28 |
4 |
B |
$49.70 |
$2,786,084 |
I/I |
55,258 |
14,336,671 |
2.25 |
-83% |
|
| Baker Felix |
Director |
– • • |
2022-01-27 |
4 |
B |
$51.59 |
$13,573,519 |
I/I |
262,259 |
14,285,631 |
2.25 |
-83% |
|
| Baker Felix |
Director |
– • • |
2022-01-25 |
4 |
B |
$58.90 |
$323,934 |
I/I |
5,500 |
14,027,837 |
2.25 |
-87% |
|
| Baker Felix |
Director |
– • • |
2022-01-24 |
4 |
B |
$56.39 |
$20,905,291 |
I/I |
362,197 |
14,022,337 |
2.25 |
-87% |
|
| Baker Felix |
Director |
– • • |
2022-01-21 |
4 |
B |
$56.57 |
$7,577,571 |
I/I |
133,414 |
13,660,140 |
2.25 |
-87% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2022-01-20 |
4 |
AS |
$62.72 |
$447,494 |
D/D |
(6,950) |
51,541 |
|
-88% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2022-01-20 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
58,491 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2021-12-20 |
4 |
AS |
$86.60 |
$608,831 |
D/D |
(6,950) |
51,541 |
|
-93% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2021-12-20 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
58,491 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2021-11-22 |
4 |
AS |
$96.82 |
$689,113 |
D/D |
(6,950) |
51,541 |
|
-92% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2021-11-22 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
58,491 |
|
- |
|
| Borgeson John A. |
See Remarks |
• – – |
2021-11-10 |
4 |
AS |
$115.16 |
$101,111 |
D/D |
(876) |
169,443 |
|
-93% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2021-10-20 |
4 |
AS |
$111.56 |
$776,824 |
D/D |
(6,950) |
51,541 |
|
-92% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2021-10-20 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
58,491 |
|
- |
|
| Baker Julian |
Director |
– • • |
2021-09-30 |
4 |
B |
$95.83 |
$8,330,572 |
I/I |
86,932 |
13,526,726 |
2.25 |
-38% |
|
101 Records found
|
|
Page 1 of 5 |
|
|
0.05 (1.5%) 
